US Patent 7,988,998: Scope, Claims, and US Landscape for Once-Daily Controlled-Release Tramadol Tablets

What is US 7,988,998 claiming at a high level?

US 7,988,998 claims an oral, once-daily controlled-release tramadol tablet built as a core plus compression coat system designed to deliver:

Onset of analgesic effect within 2 hours after a first dose
Sustained effect for at least 24 hours
A release profile where core release is slower than coat release
Specific core and coat compositions and quantitative pharmacokinetic (PK) and in vitro dissolution targets that bound performance

The claims’ center of gravity is not “tramadol once daily” generically. It is the combination of:

a cross-linked high amylose starch controlled-release core matrix, and
a compression coat made from polyvinyl acetate (PVA) and polyvinylpyrrolidone (PVP) at a defined 8:2 weight ratio, with a defined coat solid fraction,
tied to tight PK thresholds, Cmax shaping, and in vitro dissolution bands.

What is the independent claim (Claim 1) really locking up?

Claim 1 defines a once-daily oral controlled-release tramadol tablet with the following mandatory structural and performance features:

Structural elements

Core
- Contains tramadol dispersed in a first controlled-release matrix comprising cross-linked high amylose starch
- Core tramadol loading: ~10 to ~70 wt% of the core
Compression coat formed over the core
- Coat composition: tramadol dispersed in a mixture of PVA and PVP
- Polymer ratio: PVA:PVP = ~8:2 (w/w)
- Coat makeup: polymer+tramadol mixture constitutes ~30% to ~65% by weight of the coat
- Core-release is slower than coat-release
Dosage form
- The composition is a tablet

Performance elements (pharmacology proxy and PK constraints)

Onset and duration
- After initial administration of one dose, onset of analgesic effect within 2 hours
- Analgesic effect continues for at least 24 hours
The claim includes performance-defined behavior, which the dependent claims then operationalize via plasma concentration thresholds, metabolite exposure, Cmax shaping, and dissolution time-course.

Which claim sets expand scope by dose-specific PK targets?

Claims 2 to 12 create dose-anchored PK envelopes that narrow the product space to compositions producing mean exposure above defined thresholds for long durations.

100 mg tramadol: Claim 5–6

Dose: 100 mg
Mean plasma:
- ≥ 50 ng/mL within 2 hours
- ≥ 50 ng/mL for at least 22 hours
Dependent extension:
- ≥ 50 ng/mL for at least 23 hours (Claim 6)

200 mg tramadol: Claim 2–4

Dose: 200 mg
Mean plasma:
- ≥ 100 ng/mL within 2 hours
- ≥ 100 ng/mL for at least 22 hours
Dependent extensions:
- ≥ 100 ng/mL for at least 23 hours (Claim 3)
- ≥ 100 ng/mL for at least 24 hours (Claim 4)

300 mg tramadol: Claim 7–9

Dose: 300 mg
Mean plasma:
- ≥ 150 ng/mL within 2 hours
- ≥ 150 ng/mL for at least 22 hours
Dependent extensions:
- ≥ 150 ng/mL for at least 23 hours (Claim 8)
- ≥ 150 ng/mL for at least 24 hours (Claim 9)

400 mg exposure: Claim 10–12

Claim 10: upon initial administration of 400 mg
- ≥ 200 ng/mL for at least 22 hours
Dependent tightening:
- ≥ 190 ng/mL for at least 23 hours (Claim 11)
- ≥ 180 ng/mL for at least 24 hours (Claim 12)

Business implication: these dose-specific PK bands are not trivial; they force alignment between formulation release kinetics and systemic exposure, which many “once-daily” tramadol products fail when tested under the same dosing and evaluation conditions.

How do Cmax and C24h/C24 constraints shape exposure (claims 13–16)?

Claims 13 to 16 restrict the “shape” of plasma concentration rather than only the level.

Cmax caps

Claim 13 (100 mg): mean Cmax < 100 ng/mL
Claim 14 (300 mg): mean Cmax < 300 ng/mL

Cmax-to-late-level ratios

Claim 15 (300 mg): Cmax < 2 times mean plasma concentration at 24 hours (C24h)
Claim 16 (400 mg): Cmax < 2.3 times mean plasma concentration at 24 hours (C24)

Business implication: these are “burst control” boundaries, targeting flatter profiles. Even if a formulation meets a late exposure target, it may fall outside if Cmax overshoots early.

What metabolite exposure is included, and why it matters (claims 17–20)?

The claims explicitly cover O-desmethyltramadol (metabolite exposure), which is often used to support analgesic-related exposure and PK matching.

100/200/300 mg: Claim 17–19

Claim 17 (100 mg):
- O-desmethyltramadol mean ≥ 11 ng/mL within 2 hours
- Mean ≥ 12 ng/mL for at least 24 hours
Claim 18 (200 mg):
- Mean ≥ 24 ng/mL within 2 hours
- Mean ≥ 25 ng/mL for at least 24 hours
Claim 19 (300 mg):
- Mean ≥ 32 ng/mL within 2 hours
- Mean ≥ 32 ng/mL for at least 24 hours

400 mg: Claim 20

Claim 20 (400 mg):
- Mean O-desmethyltramadol ≥ 50 ng/mL within 2 hours
- Mean ≥ 50 ng/mL for at least 24 hours

Business implication: metabolite exposure constraints add another axis. A formulation that matches tramadol levels can still fall out of scope if it under-delivers metabolite AUC or late levels.

What dissolution and release-rate bands are specified (claims 21–23)?

This is a critical scope lever because it provides an in vitro performance signature tied to in vivo outcome claims.

Release-time distribution: Claim 21

After administration, the claim bounds the percent of agent released across time windows:

10% to 40% released between 0 and ~2 hours
30% to 60% released between ~2 and ~7 hours
50% to 80% released between ~7 and ~12 hours
80% to 100% released after ~20 hours

This expresses a delayed-release profile with controlled early release and near-complete release by ~20 hours.

USP apparatus Type 1 dissolution bands: Claims 22–23

All dissolution bands are defined with:

HPLC-USP apparatus Type 1
100 rpm
50 mM sodium phosphate buffer
pH 6.8

Two sets of band targets:

Claim 22 dissolution ranges:
- 5% to 30% at 1 hour
- 15% to 40% at 2 hours
- 20% to 50% at 4 hours
- 30% to 70% at 8 hours
- 40% to 90% at 12 hours
- 50% to 100% at 16 hours
- 60% to 100% at 24 hours
Claim 23 dissolution ranges:
- 10% to 25% at 1 hour
- 15% to 30% at 2 hours
- 25% to 40% at 4 hours
- 40% to 55% at 8 hours
- 60% to 75% at 12 hours
- 70% to 90% at 16 hours
- 90% to 100% at 24 hours

Business implication: the dual dissolution bands indicate at least two formulation variants or two claim “tracks” within the same architecture. A design-around that matches one dissolution band may still be captured by the other if the product falls inside the relevant range.

What formulation parameter details are specified in dependent claims (claims 24–29)?

These claims further constrain material composition.

Tablet strength pins

Claim 24: Claim 22 plus 200 mg tramadol
Claim 25: Claim 23 plus 200 mg tramadol

Core loading window: Claim 26

Tramadol in core: ~20 to ~60 wt% (subset of Claim 1’s ~10 to ~70)

Coat loading window: Claim 27

Tramadol in coat: ~15 to ~40 wt% (subset)

Polymer molecular weight ranges

Claim 28: PVA molecular weight ~100,000 to ~1,000,000
Claim 29: PVP molecular weight ~10,000 to ~100,000

Business implication: the molecular weight windows limit polymer selection, making it harder to swap grades without affecting dissolution and exposure.

Scope map: what an accused product would have to include to land inside the claims

Below is a claim-structure “gate” view showing the minimum required elements by scope layer.

Scope layer	Claimed constraint	Where it appears
Dosage form	oral tablet	Claim 1
Architecture	core + compression coat with core-release slower than coat-release	Claim 1
Core composition	tramadol dispersed in cross-linked high amylose starch matrix	Claim 1
Core loading	tramadol ~10–~70 wt% of core (or ~20–~60 wt% subset)	Claim 1, Claim 26
Coat composition	tramadol dispersed in PVA:PVP = 8:2, coat includes ~30–~65 wt% of that mixture	Claim 1
Coat loading	tramadol in coat ~15–~40 wt%	Claim 27
Polymer grade	PVA MW 100k–1,000k, PVP MW 10k–100k	Claims 28–29
Exposure and duration	analgesic effect onset ≤2 hours and lasts ≥24 hours	Claim 1
Tram BM PK thresholds	mean plasma level thresholds by dose and duration	Claims 2–12
Cmax shaping	Cmax and Cmax/C24 ratio constraints	Claims 13–16
Metabolite exposure	O-desmethyltramadol thresholds by dose and duration	Claims 17–20
In vitro signature	time-release distribution and USP dissolution bands	Claims 21–23

How strong is the “design-around” surface area based on claim architecture?

The claims combine:

Composition constraints (cross-linked high amylose starch core; PVA/PVP coat with exact ratio and polymer MW bounds in dependent claims)
Performance constraints (in vivo mean plasma thresholds at multiple doses, Cmax limits and ratio constraints, and metabolite thresholds)
In vitro constraints (release windows and dissolution bands with defined apparatus and conditions)

That combination narrows practical design-around options. A competing product would need to change one of the architecture fundamentals or produce a non-infringing release/exposure signature that falls outside the bounded bands.

What is the patent landscape implication (US 7,988,998 type of claim set)?

With only the claims text provided, the landscape can be described at the level of claim-coverage mechanics rather than identifying particular competing patents by number.

Coverage mechanics that tend to matter for tramadol CR tablets

Core technology lock-in: cross-linked high amylose starch as a controlled-release matrix for tramadol in a core
Coating mechanism lock-in: compression coat over the core containing tramadol dispersed in a PVA/PVP system at fixed ratio
Release-order requirement: core releases slower than coat
Quantified PK envelope: multiple dose-specific mean concentration and duration limits
Early/late balance: Cmax caps and Cmax-to-24h ratio constraints
Metabolite matching: O-desmethyltramadol mean levels at 2h and 24h

In practice, these elements typically drive clearance assessments because they define the “testable” product phenotype. Patent risk usually tracks whether a generic or follow-on product can reproduce the same in vitro dissolution signature and in vivo PK profile.

Key Takeaways

US 7,988,998 claim scope is built around a specific tablet architecture: a tramadol core using cross-linked high amylose starch plus a compression coat with tramadol in a PVA/PVP (8:2) mixture where core release is slower than coat release.
Scope is performance-bounded: claims require analgesic onset within 2 hours and duration ≥24 hours, backed by multiple dose-specific mean plasma concentration bands for tramadol and O-desmethyltramadol, plus Cmax and Cmax/C24h constraints.
In vitro dissolution is tightly defined: USP Type 1 at 100 rpm in 50 mM phosphate buffer pH 6.8 with specified time-course ranges, plus a release window map by hour.
Dependent claims narrow formulation choices further: tramadol loading ranges in core and coat and polymer molecular weight windows for PVA and PVP.
For freedom-to-operate analysis, the product must clear not only the composition and architecture constraints, but also the quantified PK/metabolite and dissolution phenotype.

FAQs

1) Does the patent cover only tramadol free base, or also salts?

The claims explicitly cover “tramadol or a salt thereof” for the metabolite exposure portions (Claims 17–20), and Claim 1 describes tramadol broadly. Salt forms are therefore within scope where the dependent claim language applies.

2) What makes Claim 1 narrower than a generic “once-daily tramadol” claim?

Claim 1 ties together the specific core matrix (cross-linked high amylose starch), the compression coat composition (PVA/PVP at 8:2), and a defined release-order relationship plus onset and duration performance.

3) Are PK thresholds only for one dose?

No. The claims include 100 mg, 200 mg, 300 mg, and 400 mg dose-specific mean plasma concentration constraints and duration requirements (Claims 2–12).

4) Do the claims require O-desmethyltramadol testing?

Yes, metabolite constraints appear in Claims 17–20 and require mean O-desmethyltramadol thresholds at 2 hours and sustained ≥24-hour levels.

5) Is dissolution testing part of the claim scope?

Yes. Claims 21–23 define specific release windows and USP Type 1 dissolution bands with defined test conditions (apparatus, rpm, buffer, and pH).

References

[1] Claims text for US Patent 7,988,998 (user-provided).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	045972	⤷ Start Trial
Argentina	045973	⤷ Start Trial
Austria	390128	⤷ Start Trial
Austria	400819	⤷ Start Trial
Australia	2003275854	⤷ Start Trial
Australia	2003275855	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,988,998